Skip to main content

Table 4 RECIST 1.1. responses in patients evaluable for clinical activity

From: Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

Response

0.5 mg/kg

(N = 2)

1 mg/kg

(N = 3)

2 mg/kg

(N = 3)

3 mg/kg

(N = 3)

5 mg/kg

(N = 5)

Total

(N = 16)

Response

CR

0

0

0

0

0

0

PR

0

0

0

0

1 (20%)

1 (6.3%)

SD

1 (50.0%)

2 (66.7%)

2 (66.7%)

2 (66.7%)

1 (20%)

8 (50.0%)

PD

1 (50.0%)

1 (33.3%)

1 (33.3%)

1 (33.3%)

3 (60%)

7 (43.8%)

  1. Percentages are based on the number of subjects within each cohort
  2. CR = Complete response, PR = Partial response, SD = Stable disease, PD = Progressive disease
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us